| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Following intravenous injection, iodobenzoic acid is primarily distributed in the extracellular fluid. The plasma concentration of radioactive contrast agents such as iodobenzoic acid varies with dose and injection rate. Approximately 80% of the administered dose remains extravascular within 5 minutes of administration. However, there are exceptions, such as in the brain, nerve tissue, and testes, where tight junctions prevent drug diffusion outside the blood vessels. Following intravenous injection, iodobenzoic acid is primarily excreted unchanged via the kidneys. Its clearance pathways include glomerular filtration and tubular reabsorption of water. Approximately 83% of the administered dose is excreted 3 hours after administration, and approximately 100% after 24 hours. Metabolism/Metabolites Most of the administered dose of acetoiodic acid remains unchanged. Biological Half-Life It has been reported that the half-life of water-soluble contrast agents (such as acetoiodic acid) is approximately 4 hours. |
|---|---|
| Toxicity/Toxicokinetics |
Protein Binding
Radioactive contrast agents such as acetoiodic acid exist in plasma in free form, with less than 5% of the injected dose being bound to proteins. |
| References |
|
| Additional Infomation |
Acetyliodic acid is an aminobenzoic acid. The molecular formula of acetyliodic acid is 3-acetaminophen-2,4,6-triiodobenzoic acid. It was the first monomeric ionic compound used as an X-ray contrast agent. It was first synthesized by Wallingford in 1953, and an application was submitted to the U.S. Food and Drug Administration (FDA) on February 8, 1978, by Cilag Chemie AG, a subsidiary of Johnson & Johnson. In FDA records, acetyliodic acid is listed as an inactive drug. It is an iodinated radiocontrast agent used in hysterosalpingography (HSG) in the form of sodium acetyliodate. The indication for acetyliodic acid is its use as an X-ray contrast agent. Some data suggest that its renal affinity is a characteristic of its application. X-ray imaging relies on differences in tissue density caused by X-ray attenuation between the target area and surrounding tissues. The use of contrast agents can enhance contrast or render images non-visible, thereby improving the ability to distinguish pathological processes from normal tissues.
Mechanism of Action Iodine is the main component of acetoiodic acid, an element with a very high atomic density. This property causes attenuation of X-rays within the diagnostic energy range. Therefore, acetoiodic acid is a water-soluble and relatively safe iodinated contrast agent that can be used clinically via intravenous injection. |
| Molecular Formula |
C9H6I3NO3
|
|---|---|
| Molecular Weight |
556.8623
|
| Exact Mass |
556.748
|
| CAS # |
85-36-9
|
| PubChem CID |
6806
|
| Appearance |
White to off-white solid powder
|
| Density |
2.8±0.1 g/cm3
|
| Boiling Point |
547.1±50.0 °C at 760 mmHg
|
| Flash Point |
284.7±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.802
|
| LogP |
1.04
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
300
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
IC1=C(C(=O)O[H])C(=C([H])C(=C1N([H])C(C([H])([H])[H])=O)I)I
|
| InChi Key |
GNOGSFBXBWBTIG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H6I3NO3/c1-3(14)13-8-5(11)2-4(10)6(7(8)12)9(15)16/h2H,1H3,(H,13,14)(H,15,16)
|
| Chemical Name |
3-acetamido-2,4,6-triiodobenzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 5.6 mg/mL (~10.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7958 mL | 8.9789 mL | 17.9578 mL | |
| 5 mM | 0.3592 mL | 1.7958 mL | 3.5916 mL | |
| 10 mM | 0.1796 mL | 0.8979 mL | 1.7958 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
